TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 070196 AND 071296—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
Aurora Equity Partners L.P., Golder, Thoma, Cressey Fund III Limited Partnership, Dickson Media, Inc	96–2243	07/02/96
Big Flower Press Holdings, Inc., Scanforms, Inc., Scanforms, Inc	96–2244	07/02/96
Takasago International Corporation, Monsanto Company, The nutraSweet Kelco Company	96–2249	07/02/96
TRW Inc., TRW Inc., TRW REDI Property Data	96–2252	07/02/96
Cabletron Systems, Inc., Network Express, Inc., Network Express, Inc	96–2048	07/03/96
CCA Financial, Inc., Un-Ltd Holdings, Inc., Nelco Ltd	96–2213	07/03/96
CalEnergy Company, Inc., David H. Dewhurst III, Falcon Seaboard Resources, Inc.	96–2234	07/03/96
Jordan Industries, Inc., Abram Ackerman, Viewsonics, Inc	96–2109	07/08/96
Central Garden & Pet Company, Kenlin Pet Supply, Inc., Kenlin Pet Supply, Inc	96–2162	07/08/96
Morton M. Lapides, Sr., The Seagram Company Ltd., Winterland Concessions Company	96–2253	07/08/96
Edward K. Mullen, Nelson-Ball Paper Products, Inc., Nelson-Ball Paper Products, Inc	96–2257	07/08/96
Trinity Industries, Inc., Transcisco Industries, Inc., Transcisco Industries, Inc	96–2258	07/08/96
U.S. Office Products Company, Vassilios Sirpolaidis and Lynne Sirpolaidis, Mile high Office Supply and Office Extra, L.L.C	96–2259	07/08/96
General Electric Company, James Elliott, Universal Data Consultants, Inc	96–2261	07/08/96
General Electric Company, Ken Callaham, Universal Data Consultants, Inc	96–2263	07/08/96
Integrated health Services, Inc., Capstone Pharmacy Services, Inc., Capstone Pharmacy Services, Inc	96–2265	07/08/96
Capstone Pharmacy Services, Inc., Integrated Health Services, Inc., Symphony Pharmacy Services, Inc	96–2266	07/08/96
JP Foodservice, Inc., ''Z'' Leasing Co. (General Partnership), ''Z'' Leasing Co. (General Partnership)	96–2269	07/08/96
JP Foodservice, Inc., Valley Industries, Inc., Valley Industries, Inc	96–2270	07/08/96
Harron Communications Corp., Pegasus Communications Corporation, Pegasus Communications Corporation	96–2271	07/08/96
Marshall W. Pagon, Pegasus Communications Corp., Pegasus Communications Corp	96–2272	07/08/96
Ford Motor Company, Shirley W. Gibson, Monarch Leasing Company	96–2274	07/08/96
AnnTaylor Stores Corporation, Cygne Designs, Inc., Cygne Designs, Inc	96–2275	07/08/96
Bandai Co. Ltd., The Upper Deck Company, The Upper Deck Company LLC	96–2279	07/08/96
ARAMARK Corporation, Crest Uniform Company, Inc., Crest Uniform Company, Inc	96–2282	07/08/96
U.S. Office Products Company, McWhorter's Stationery Company, Inc., McWhorter's Stationery Company, Inc	96–2290	07/08/96
Schnuck Markets, Inc.,Seessels Holdings, Inc.,seessels Holdings, Inc	96–2189	07/10/96
U.S. Diagnostic Labs Inc., HEICO Corporation, MediTek Health Corporation	96–2297	07/10/96
Mr. Donald Gales, J. Duncan McDuff, Regent Investments Inc., Mid-Atlantic Investments Inc	96–1862	07/11/96
Mr. Donald Gales, Mr. Vincent J. Mastracco, Jr., Regent Investments, Inc., Mid-Atlantic Investments, Inc	96–1863	07/11/96
The Hitchcock Alliance, Gifford Medical Center, Gifford Medical Center	96–2157	07/11/96
American Radio Systems Corporation, Triad Capital Management, Inc., Triad Capital Management Inc	96–2190	07/11/96
WPG Corporate Development Associates IV, L.P., GHB Charitable Trust #1, Any-Kind Check Cashing Centers, Inc. and U.S. Check	96–2233	07/11/96
TPG Partners, L.P., AT&T Corporation, AT&T Paradyne Corporation & Lucient Technologies, Inc	96–2248	07/11/96
Kokusai Denshin Denwa Co. Ltd., Pacific Gateway Exchange, Inc., Pacific Gateway Exchange, Inc	96–2285	07/11/96
Olympus Private Placement Fund, L.P., Dr. Manfred George Krukemeyer (a resident of Germany), Paracelsus Healthcare Corporation	96–2291	07/11/96
Alco Standard Corporation, The Computer Group, Inc., The Computer Group, Inc	96–2293	07/11/96
Blackstone Capital Partners II Merchant Banking Fund LP, Golder, Thoma, Cressey Fund III Limited Partnership, Prime Succession, Inc	96–2307	07/11/96
Sanwa Shutter Corporation, Bessemer Securities Corporation, Overhead Door Incorporated	96–2325	07/11/96
Bankers Trust New York Corporation, BT Capital Funding Corporation, BT Capital Funding Corporation	96–2245	07/12/96

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton, Contact Representatives

Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202)326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 96–18619 Filed 7–22–96; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Projects:

Title: State corrective Action Plans for the Aid to Families with Dependent Children (AFDC) Program.

OMB No.: 0970–0027.

Description: States with excessive overpayment error rates or excessive negative case error rates submit information about: (1) Their most common types of errors, (2) the causes for those errors, and (3) their intended actions to reduce those errors. The Administration for Children and Families then uses this information to help States direct their resources toward the most efficient and effective corrective action techniques.

Respondents: State, Local or Tribal Govt.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Plan	27	1	160	4,320
Estimated Total Annual Burden Hours				4,320

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: July 17, 1996.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 96–18558 Filed 7–22–96; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

[Docket No. 96M–0216]

Biomira Diagnostics, Inc.; Premarket Approval of TRUQUANT® BR™ RIA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application submitted by Thomas Tsakeris, Devices and Diagnostics Consulting Group, Rockville, MD, U.S. Representative for Biomira Diagnostics Inc., 30 Meridian Rd., Rexdale, ON, Canada, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of TRUQUANT® BR™ RIA. After reviewing the recommendation of the Immunology Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of March 29, 1996, of the approval of the application.

DATES: Petitions for administrative review by August 22, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Peter E. Maxim, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–1293.

SUPPLEMENTARY INFORMATION: On February 24, 1995, Thomas M. Tsakeris, Devices and Diagnostics Consulting Group, Rockville, MD, U.S. Representative for Biomira Diagnostics, Inc., Rexdale, ON, Canada, submitted to CDRH an application for premarket approval of TRUQUANT® BR™ RIA. The device is an in vitro diagnostic device indicated for quantitative determination of CA 27.29 antigen in serum or EDTA plasma of patients previously treated for Stage II or Stage III breast cancer. Serial testing for CA 27.29 antigen with TRUQUANT® BR™ RIA in patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of recurrence.

On September 21, 1995, the Immunology Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On March 29, 1996, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before August 22, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.